Go Pro
→ This tiny piece of glass could be bigger than GPUs (From Brownstone Research) (Ad)tc pixel Free OACC Stock Alerts

Oaktree Acquisition Corp. III Life Sciences (OACC) Competitors

Oaktree Acquisition Corp. III Life Sciences logo
$10.73 -0.02 (-0.19%)
As of 03:19 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

OACC vs. OCSL, RHLD, FSCO, GSBD, and RPC

Should you buy Oaktree Acquisition Corp. III Life Sciences stock or one of its competitors? MarketBeat compares Oaktree Acquisition Corp. III Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oaktree Acquisition Corp. III Life Sciences include Oaktree Specialty Lending (OCSL), Resolute Holdings Management (RHLD), FS Credit Opportunities (FSCO), Goldman Sachs BDC (GSBD), and Ridgepost Capital (RPC). These companies are all part of the "asset management & custody banks" industry.

How does Oaktree Acquisition Corp. III Life Sciences compare to Oaktree Specialty Lending?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) and Oaktree Specialty Lending (NASDAQ:OCSL) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Oaktree Specialty Lending has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A
Oaktree Specialty Lending$316.80M3.54$33.92M$0.4826.52

Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, Oaktree Specialty Lending has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Oaktree Specialty Lending has a consensus price target of $11.83, indicating a potential downside of 7.04%. Given Oaktree Specialty Lending's stronger consensus rating and higher possible upside, analysts plainly believe Oaktree Specialty Lending is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Oaktree Specialty Lending
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

36.8% of Oaktree Specialty Lending shares are held by institutional investors. 0.3% of Oaktree Specialty Lending shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oaktree Specialty Lending has a net margin of 14.45% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Oaktree Specialty Lending's return on equity of 9.70% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Oaktree Acquisition Corp. III Life SciencesN/A N/A N/A
Oaktree Specialty Lending 14.45%9.70%4.64%

In the previous week, Oaktree Specialty Lending had 12 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 13 mentions for Oaktree Specialty Lending and 1 mentions for Oaktree Acquisition Corp. III Life Sciences. Oaktree Specialty Lending's average media sentiment score of 0.17 beat Oaktree Acquisition Corp. III Life Sciences' score of 0.00 indicating that Oaktree Specialty Lending is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oaktree Acquisition Corp. III Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oaktree Specialty Lending
1 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Oaktree Specialty Lending beats Oaktree Acquisition Corp. III Life Sciences on 11 of the 11 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Resolute Holdings Management?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) and Resolute Holdings Management (NYSE:RHLD) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Comparatively, Resolute Holdings Management has a beta of -1.29, meaning that its share price is 229% less volatile than the broader market.

Oaktree Acquisition Corp. III Life Sciences has higher earnings, but lower revenue than Resolute Holdings Management.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A
Resolute Holdings Management$462.05M2.23-$5.92M$5.4324.30

In the previous week, Resolute Holdings Management had 1 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 2 mentions for Resolute Holdings Management and 1 mentions for Oaktree Acquisition Corp. III Life Sciences. Resolute Holdings Management's average media sentiment score of 1.77 beat Oaktree Acquisition Corp. III Life Sciences' score of 0.00 indicating that Resolute Holdings Management is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oaktree Acquisition Corp. III Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Resolute Holdings Management
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Resolute Holdings Management has a net margin of 4.21% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Resolute Holdings Management's return on equity of 5.20% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Oaktree Acquisition Corp. III Life SciencesN/A N/A N/A
Resolute Holdings Management 4.21%5.20%2.43%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Resolute Holdings Management
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Resolute Holdings Management beats Oaktree Acquisition Corp. III Life Sciences on 6 of the 7 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to FS Credit Opportunities?

FS Credit Opportunities (NYSE:FSCO) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FS Credit Opportunities
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FS Credit Opportunities$163.59M6.21N/AN/AN/A
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A

In the previous week, FS Credit Opportunities had 2 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 3 mentions for FS Credit Opportunities and 1 mentions for Oaktree Acquisition Corp. III Life Sciences. FS Credit Opportunities' average media sentiment score of 1.22 beat Oaktree Acquisition Corp. III Life Sciences' score of 0.00 indicating that FS Credit Opportunities is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
FS Credit Opportunities
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oaktree Acquisition Corp. III Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Net Margins Return on Equity Return on Assets
FS Credit OpportunitiesN/A N/A N/A
Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A

FS Credit Opportunities has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

36.4% of FS Credit Opportunities shares are owned by institutional investors. 0.3% of FS Credit Opportunities shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

FS Credit Opportunities beats Oaktree Acquisition Corp. III Life Sciences on 6 of the 7 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Goldman Sachs BDC?

Goldman Sachs BDC (NYSE:GSBD) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Goldman Sachs BDC has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

Goldman Sachs BDC currently has a consensus price target of $8.75, suggesting a potential downside of 9.93%. Given Goldman Sachs BDC's stronger consensus rating and higher probable upside, research analysts clearly believe Goldman Sachs BDC is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Goldman Sachs BDC
3 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.57
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

28.7% of Goldman Sachs BDC shares are owned by institutional investors. 0.1% of Goldman Sachs BDC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Goldman Sachs BDC has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Goldman Sachs BDC$365.57M2.99$119.27M$0.5218.68
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A

In the previous week, Goldman Sachs BDC had 12 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 13 mentions for Goldman Sachs BDC and 1 mentions for Oaktree Acquisition Corp. III Life Sciences. Goldman Sachs BDC's average media sentiment score of 0.62 beat Oaktree Acquisition Corp. III Life Sciences' score of 0.00 indicating that Goldman Sachs BDC is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Goldman Sachs BDC
1 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oaktree Acquisition Corp. III Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Goldman Sachs BDC has a net margin of 17.19% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Goldman Sachs BDC's return on equity of 10.92% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Goldman Sachs BDC17.19% 10.92% 4.59%
Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A

Summary

Goldman Sachs BDC beats Oaktree Acquisition Corp. III Life Sciences on 11 of the 11 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Ridgepost Capital?

Ridgepost Capital (NYSE:RPC) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Ridgepost Capital had 10 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 11 mentions for Ridgepost Capital and 1 mentions for Oaktree Acquisition Corp. III Life Sciences. Ridgepost Capital's average media sentiment score of 0.69 beat Oaktree Acquisition Corp. III Life Sciences' score of 0.00 indicating that Ridgepost Capital is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ridgepost Capital
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oaktree Acquisition Corp. III Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ridgepost Capital has a net margin of 9.03% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Ridgepost Capital's return on equity of 22.54% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ridgepost Capital9.03% 22.54% 9.78%
Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A

Ridgepost Capital has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ridgepost Capital$297.35M3.21$19.50M$0.2534.90
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A

Ridgepost Capital presently has a consensus target price of $11.00, indicating a potential upside of 26.07%. Given Ridgepost Capital's stronger consensus rating and higher probable upside, equities analysts plainly believe Ridgepost Capital is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ridgepost Capital
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Oaktree Acquisition Corp. III Life Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

48.1% of Ridgepost Capital shares are owned by institutional investors. 11.8% of Ridgepost Capital shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ridgepost Capital has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

Summary

Ridgepost Capital beats Oaktree Acquisition Corp. III Life Sciences on 12 of the 12 factors compared between the two stocks.

Get Oaktree Acquisition Corp. III Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for OACC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OACC vs. The Competition

Export
MetricOaktree Acquisition Corp. III Life SciencesCapital Markets IndustryFinance SectorNASDAQ Exchange
Market Cap$263.77M$5.59B$14.03B$12.94B
Dividend YieldN/A7.40%5.89%10.20%
P/E RatioN/A37.8729.0124.78
Price / SalesN/A1,200.69503.50108.19
Price / CashN/A48.3030.2237.44
Price / BookN/A3.733.716.43
Net IncomeN/A$417.15M$1.31B$347.27M
7 Day Performance-0.28%0.78%0.27%2.54%
1 Month Performance0.15%0.23%0.73%-1.00%
1 Year Performance2.48%6.45%12.54%23.33%

Oaktree Acquisition Corp. III Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OACC
Oaktree Acquisition Corp. III Life Sciences
N/A$10.73
-0.2%		N/A+2.8%$263.77MN/AN/AN/A
OCSL
Oaktree Specialty Lending
1.6863 of 5 stars		$11.61
flat		$11.83
+1.9%		-3.3%$1.02B$55.37M20.37N/A
RHLD
Resolute Holdings Management
1.8643 of 5 stars		$123.95
+0.2%		N/A+165.6%$1.02B$765.96M17.995,620
FSCO
FS Credit Opportunities
N/A$4.95
-0.1%		N/A-32.1%$1.00B$163.59MN/AN/A
GSBD
Goldman Sachs BDC
2.7445 of 5 stars		$8.61
+0.0%		$8.50
-1.3%		-13.3%$969.22M$86.61M13.25N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OACC) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
China is not hedging. It's escaping.
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...
Behind the Markets | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
SpaceX is NOT the #1 IPO of 2026
A lesser known AI company is growing faster than both SpaceX and OpenAI. Its coding business reportedly grew f...
The Oxford Club | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel
Now that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)
The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was...
Brownstone Research | Sponsoredtc pixel